Name | Title | Contact Details |
---|
Camurus is a Swedish science-led biopharmaceutical company committed to improving the lives of patients with severe and chronic diseases. We empower patients, support caregivers and create value for society by developing and giving access to innovative, long-acting medicines. To fulfill our commitment, we are determined to conduct our business in a sustainable manner. New drug products with best-in-class potential are conceived based on the companys proprietary FluidCrystal® technology and extensive R&D expertise. Camurus clinical pipeline includes products for the treatment of treatment of opioid dependence, cancer, and endocrine disorders, which are developed in-house and in collaboration with international pharmaceutical companies. The companys shares are listed on Nasdaq Stockholm under the ticker CAMX.
Saneron CCEL Therapeutics is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Croda is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Agenus is an immuno-oncology company driven by innovation and speed. Our goal is to treat cancers with novel combinations utilizing our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines and adjuvants. In addition to a broad portfolio, we have an accomplished team of scientists, novel technology platforms and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. With our remarkable combination of science and people, we believe that we are uniquely positioned to bring curative treatments to cancer patients.
Most patients who are prescribed blockbuster therapies today don`t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher`s platform identifies which drug will work based on the patient`s fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.